By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Galectin Therapeutics 

7 Wells Avenue, Suite #34

Newton  Massachusetts  02459  U.S.A.
Phone: 617-559-0033 Fax: 617-928-3450


Company News
Galectin Therapeutics Announces Issuance Of U.S. Patent For GR-MD-02 In Diabetic Nephropathy 9/15/2014 8:02:00 AM
Galectin Therapeutics To Present At Aegis Capital Corporation 2014 Healthcare And Technology Conference 9/10/2014 7:53:49 AM
Galectin Therapeutics Reports Second Quarter 2014 Financial Results 8/8/2014 10:53:36 AM
Galectin Therapeutics Receives U.S. Patent For GR-MD-02 Composition Of Matter 8/5/2014 8:30:44 AM
Galectin Therapeutics Responds To Class Action Lawsuit 8/4/2014 8:13:51 AM
Galectin Therapeutics Issues Statement on GR-MD-02 Development Program 7/30/2014 10:49:19 AM
Galectin Therapeutics To Host Webcast To Discuss Findings From Cohort 2 Of Phase 1 Clinical Trial Of GR-MD-02 In Fatty Liver Disease With Advanced Fibrosis 7/25/2014 8:00:03 AM
Galectin Therapeutics Announces First Patient Dosed In Cohort 1 Of Phase 1B Clinical Trial Of GR-MD-02 In Combination With Ipilimumab In Metastatic Melanoma 7/22/2014 11:20:42 AM
Galectin Therapeutics Added To Russell 2000 Index 7/9/2014 10:33:53 AM
Galectin Therapeutics Announces That Oral Treatment With Galectin-3 Inhibitor GR-MD-02 Is Efficacious In Preclinical Model Of Fatty Liver Disease With Fibrosis 6/23/2014 7:30:41 AM